Metastatic Solid Tumors Market Assessment, By Type [Sarcomas, Carcinomas, Lymphomas], By Treatment [Chemotherapy, Immunotherapy, Targeted Therapy, Others], By Route of Administration [Oral, Parenteral, Others], By End-user [Hospitals, Specialty Clinics, O
Description
Global metastatic solid tumors market is projected to witness a CAGR of 7.59% during the forecast period 2025-2032, growing from USD 73.86 billion in 2024 to USD 132.58 billion in 2032. The market’s growth can be attributed to the rising prevalence of cancer, rapid advancements in personalized medicines, and increasing accessibility of targeted therapies. The American Cancer Society estimates that over 2 million new cancer cases will be reported in the United States in 2025.
Additionally, the market’s growth is also supported by advancements in early cancer detection technologies and gene editing technologies and artificial intelligence (AI)- based oncology platforms. Healthcare sectors across the globe are recognizing the threat posed by metastatic solid tumors and prioritizing investments and innovations in oncology, providing lucrative growth opportunities for the market.
Rising Incidence of Late-Stage Cancer Drive Market Growth
The sharp rise in late-stage cancer diagnoses across the globe is one of the major drivers of the metastatic solid tumors market. A large number of cancer cases are diagnosed at an advanced stage, where curative treatment options are limited. This has led to increased demand for therapies that manage disease progression and prolong survival. Improved diagnostic imaging, liquid biopsies, and biomarker testing are enabling earlier detection of metastasis, allowing for timely treatment interventions. As awareness campaigns expand and cancer screening becomes more widespread in developed nations, early diagnosis rates are improving and fueling the demand for robust therapeutic options such as immune checkpoint inhibitors, tyrosine kinase inhibitors, and PARP inhibitors. Furthermore, the emotional and economic toll of metastatic disease on families has heightened pressure on healthcare systems and pharmaceutical companies to develop novel, cost-effective therapies. As a result, investment in translational oncology research and precision drug development is intensifying. For instance, in December 2024, Daiichi Sankyo Company, Limited presented its clinical research across its oncology portfolio at the San Antonio Breast Cancer Symposium, the 2024 ESMO Asia, and the American Society of Hematology. The company’s therapies showed advancements in previously treated HER2 positive metastatic breast cancer.
Technological Advancements Support Market Expansion
Technological advancements are enabling the availability of novel treatment solutions and early detection of metastatic solid tumors with the help of genomic testing. Next generation sequencing and biomarker driven therapies are allowing medical professionals to tailor their treatments on the basis of the patient’s unique genetic profile, ensuring minimal side effects and improvements in treatment outcomes. Leading pharmaceutical companies and research organizations across the globe are working on introducing new technologies and therapeutic solutions to effectively treat different metastatic solid tumors. For instance, in August 2024, the United States Food and Drug Administration (FDA) provide accelerated approval to the first engineered cell therapy for a solid tumor, afamitresgene autoleucel (afami-cel, Tecelra). Such breakthroughs and approvals are expected to encourage further investments in clinical adoption and research activities associated with advanced cell therapies, allowing the key players to deliver advanced therapeutic solutions and provide lucrative growth opportunities for the market.
Targeted Therapy Accounts for Significant Share of the Market
The segment’s expansion can be attributed to the various advantages associated with the utilization of targeted therapies. Unlike chemotherapy, which indiscriminately affects healthy and cancerous cells, targeted therapies block specific molecular pathways involved in tumor growth and spread. The rising adoption of next-generation sequencing and biomarker-guided treatment strategies has expanded the eligible patient population for targeted agents. These therapies are often used in first- or second-line treatment of metastatic tumors and show improved efficacy and tolerability. Furthermore, the entry of biosimilars and generics for key targeted therapies is increasing their accessibility. As the requirement for personalized treatment regimens increases, the demand for targeted therapies is expected to increase, providing lucrative growth opportunities for the market. Thus, leading pharmaceutical companies across the globe are focusing on launching new therapies and regulatory bodies are ensuring that they receive accelerated approvals. For instance, in March 2025, China’s National Medical Products Administration (NMPA) approved Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's SKB107, an (Radionuclide Drug Conjugate) RDC that targets bone metastases in solid tumors.
North America Holds Major Market Share
The region’s dominance can be attributed to the strong presence of leading pharmaceutical companies, increasing investments in the oncology segment, rising focus on research and development activities, and growing threat of cancer in countries such as the United States and Canada. As per the estimates of the Canadian Cancer Society, 2 in 5 Canadians are expected to be diagnosed with cancer during their lifetime. Additionally, regulatory bodies such as the FDA have established accelerated approval pathways for therapies that target metastatic solid tumors, resulting in increasing entry of novel therapeutic solutions. Furthermore, Canada’s healthcare system is also focusing on increasing investments towards precision diagnostics and oncology services, providing lucrative growth opportunities for the market. The combination of regulatory support, high awareness among the public about cancer and the various treatment options available, and technological innovations are supporting the market’s expansion in North America.
Impact of the U.S. Tariff on Global Metastatic Solid Tumors Market
The recently imposed tariffs are expected to significantly impact on the market as it relies heavily upon international collaborations and complex supply chains. In order to limit the potential impact of the tariffs, leading pharmaceutical companies are focusing on diversification of their supply chains and expansion of their domestic production capacity. However, such measures will require considerable investment and time and will not be able to provide immediate relief from the impact of the tariffs. Due to the disruptions in supply chains, the availability of treatments for metastatic solid tumors is expected to decrease, resulting in increased treatment costs and unavailability of essential cancer therapies for economically weaker patient population.
Key Players Landscape and Outlook
The key players of the market are focusing on research and development activities and product innovations to bolster the availability of new therapeutic solutions and expand their presence in the market. For instance, in April 2024, AstraZeneca PLC’s and Daiichi Sankyo Company, Limited’s ENHERTU (fam-trastuzumab deruxtecan-nxki) received approval in the United States for treating adults with metastatic or unresectable HER2-positive solid tumors that have received systemic treatment but haven't received satisfactory outcomes. The approval was granted after the drug secured the breakthrough therapy designation in the United States and was provided under their real-time oncology review program. Such approvals are incentivizing the key players of the market to invest in research and development activities and positively influencing the market’s expansion.
Additionally, the market’s growth is also supported by advancements in early cancer detection technologies and gene editing technologies and artificial intelligence (AI)- based oncology platforms. Healthcare sectors across the globe are recognizing the threat posed by metastatic solid tumors and prioritizing investments and innovations in oncology, providing lucrative growth opportunities for the market.
Rising Incidence of Late-Stage Cancer Drive Market Growth
The sharp rise in late-stage cancer diagnoses across the globe is one of the major drivers of the metastatic solid tumors market. A large number of cancer cases are diagnosed at an advanced stage, where curative treatment options are limited. This has led to increased demand for therapies that manage disease progression and prolong survival. Improved diagnostic imaging, liquid biopsies, and biomarker testing are enabling earlier detection of metastasis, allowing for timely treatment interventions. As awareness campaigns expand and cancer screening becomes more widespread in developed nations, early diagnosis rates are improving and fueling the demand for robust therapeutic options such as immune checkpoint inhibitors, tyrosine kinase inhibitors, and PARP inhibitors. Furthermore, the emotional and economic toll of metastatic disease on families has heightened pressure on healthcare systems and pharmaceutical companies to develop novel, cost-effective therapies. As a result, investment in translational oncology research and precision drug development is intensifying. For instance, in December 2024, Daiichi Sankyo Company, Limited presented its clinical research across its oncology portfolio at the San Antonio Breast Cancer Symposium, the 2024 ESMO Asia, and the American Society of Hematology. The company’s therapies showed advancements in previously treated HER2 positive metastatic breast cancer.
Technological Advancements Support Market Expansion
Technological advancements are enabling the availability of novel treatment solutions and early detection of metastatic solid tumors with the help of genomic testing. Next generation sequencing and biomarker driven therapies are allowing medical professionals to tailor their treatments on the basis of the patient’s unique genetic profile, ensuring minimal side effects and improvements in treatment outcomes. Leading pharmaceutical companies and research organizations across the globe are working on introducing new technologies and therapeutic solutions to effectively treat different metastatic solid tumors. For instance, in August 2024, the United States Food and Drug Administration (FDA) provide accelerated approval to the first engineered cell therapy for a solid tumor, afamitresgene autoleucel (afami-cel, Tecelra). Such breakthroughs and approvals are expected to encourage further investments in clinical adoption and research activities associated with advanced cell therapies, allowing the key players to deliver advanced therapeutic solutions and provide lucrative growth opportunities for the market.
Targeted Therapy Accounts for Significant Share of the Market
The segment’s expansion can be attributed to the various advantages associated with the utilization of targeted therapies. Unlike chemotherapy, which indiscriminately affects healthy and cancerous cells, targeted therapies block specific molecular pathways involved in tumor growth and spread. The rising adoption of next-generation sequencing and biomarker-guided treatment strategies has expanded the eligible patient population for targeted agents. These therapies are often used in first- or second-line treatment of metastatic tumors and show improved efficacy and tolerability. Furthermore, the entry of biosimilars and generics for key targeted therapies is increasing their accessibility. As the requirement for personalized treatment regimens increases, the demand for targeted therapies is expected to increase, providing lucrative growth opportunities for the market. Thus, leading pharmaceutical companies across the globe are focusing on launching new therapies and regulatory bodies are ensuring that they receive accelerated approvals. For instance, in March 2025, China’s National Medical Products Administration (NMPA) approved Sichuan Kelun-Biotech Biopharmaceutical Co Ltd's SKB107, an (Radionuclide Drug Conjugate) RDC that targets bone metastases in solid tumors.
North America Holds Major Market Share
The region’s dominance can be attributed to the strong presence of leading pharmaceutical companies, increasing investments in the oncology segment, rising focus on research and development activities, and growing threat of cancer in countries such as the United States and Canada. As per the estimates of the Canadian Cancer Society, 2 in 5 Canadians are expected to be diagnosed with cancer during their lifetime. Additionally, regulatory bodies such as the FDA have established accelerated approval pathways for therapies that target metastatic solid tumors, resulting in increasing entry of novel therapeutic solutions. Furthermore, Canada’s healthcare system is also focusing on increasing investments towards precision diagnostics and oncology services, providing lucrative growth opportunities for the market. The combination of regulatory support, high awareness among the public about cancer and the various treatment options available, and technological innovations are supporting the market’s expansion in North America.
Impact of the U.S. Tariff on Global Metastatic Solid Tumors Market
The recently imposed tariffs are expected to significantly impact on the market as it relies heavily upon international collaborations and complex supply chains. In order to limit the potential impact of the tariffs, leading pharmaceutical companies are focusing on diversification of their supply chains and expansion of their domestic production capacity. However, such measures will require considerable investment and time and will not be able to provide immediate relief from the impact of the tariffs. Due to the disruptions in supply chains, the availability of treatments for metastatic solid tumors is expected to decrease, resulting in increased treatment costs and unavailability of essential cancer therapies for economically weaker patient population.
Key Players Landscape and Outlook
The key players of the market are focusing on research and development activities and product innovations to bolster the availability of new therapeutic solutions and expand their presence in the market. For instance, in April 2024, AstraZeneca PLC’s and Daiichi Sankyo Company, Limited’s ENHERTU (fam-trastuzumab deruxtecan-nxki) received approval in the United States for treating adults with metastatic or unresectable HER2-positive solid tumors that have received systemic treatment but haven't received satisfactory outcomes. The approval was granted after the drug secured the breakthrough therapy designation in the United States and was provided under their real-time oncology review program. Such approvals are incentivizing the key players of the market to invest in research and development activities and positively influencing the market’s expansion.
Table of Contents
242 Pages
- 1. Project Scope and Definitions
- 2. Research Methodology
- 3. Impact of the U.S. Tariffs
- 4. Executive Summary
- 5. Global Metastatic Solid Tumors Market Outlook, 2018-2032F
- 5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
- 5.2. Market Share Analysis & Forecast
- 5.2.1. By Type
- 5.2.1.1. Sarcomas
- 5.2.1.2. Carcinomas
- 5.2.1.3. Lymphomas
- 5.2.2. By Treatment
- 5.2.2.1. Chemotherapy
- 5.2.2.1.1. Platinum-based Drugs
- 5.2.2.1.2. Taxanes
- 5.2.2.1.3. Anthracyclines
- 5.2.2.1.4. Others
- 5.2.2.2. Immunotherapy
- 5.2.2.3. Targeted Therapy
- 5.2.2.3.1. Tyrosine Kinase Inhibitors (TKIs)
- 5.2.2.3.2. Monoclonal Antibodies
- 5.2.2.3.3. Others
- 5.2.2.4. Other Hormonal and Supportive Care
- 5.2.3. By Route of Administration
- 5.2.3.1. Oral
- 5.2.3.2. Parenteral
- 5.2.3.3. Others
- 5.2.4. By End-user
- 5.2.4.1. Hospitals
- 5.2.4.2. Specialty Clinics
- 5.2.4.3. Others
- 5.2.5. By Region
- 5.2.5.1. North America
- 5.2.5.2. Europe
- 5.2.5.3. Asia-Pacific
- 5.2.5.4. South America
- 5.2.5.5. Middle East and Africa
- 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others – By Value, 2024)
- 5.3. Market Map Analysis, 2024
- 5.3.1. By Type
- 5.3.2. By Treatment
- 5.3.3. By Route of Administration
- 5.3.4. By End-user
- 5.3.5. By Region
- 6. North America Metastatic Solid Tumors Market Outlook, 2018-2032F
- 6.1. Market Size Analysis & Forecast
- 6.1.1. By Value
- 6.2. Market Share Analysis & Forecast
- 6.2.1. By Type
- 6.2.1.1. Sarcomas
- 6.2.1.2. Carcinomas
- 6.2.1.3. Lymphomas
- 6.2.2. By Treatment
- 6.2.2.1. Chemotherapy
- 6.2.2.1.1. Platinum-based Drugs
- 6.2.2.1.2. Taxanes
- 6.2.2.1.3. Anthracyclines
- 6.2.2.1.4. Others
- 6.2.2.2. Immunotherapy
- 6.2.2.3. Targeted Therapy
- 6.2.2.3.1. Tyrosine Kinase Inhibitors (TKIs)
- 6.2.2.3.2. Monoclonal Antibodies
- 6.2.2.3.3. Others
- 6.2.2.4. Other Hormonal and Supportive Care
- 6.2.3. By Route of Administration
- 6.2.3.1. Oral
- 6.2.3.2. Parenteral
- 6.2.3.3. Others
- 6.2.4. By End-user
- 6.2.4.1. Hospitals
- 6.2.4.2. Specialty Clinics
- 6.2.4.3. Others
- 6.2.5. By Country Share
- 6.2.5.1. United States
- 6.2.5.2. Canada
- 6.2.5.3. Mexico
- 6.3. Country Market Assessment
- 6.3.1. United States Metastatic Solid Tumors Market Outlook, 2018-2032F*
- 6.3.1.1. Market Size Analysis & Forecast
- 6.3.1.1.1. By Value
- 6.3.1.2. Market Share Analysis & Forecast
- 6.3.1.2.1. By Type
- 6.3.1.2.1.1. Sarcomas
- 6.3.1.2.1.2. Carcinomas
- 6.3.1.2.1.3. Lymphomas
- 6.3.1.2.2. By Treatment
- 6.3.1.2.2.1. Chemotherapy
- 6.3.1.2.2.1.1. Platinum-based Drugs
- 6.3.1.2.2.1.2. Taxanes
- 6.3.1.2.2.1.3. Anthracyclines
- 6.3.1.2.2.1.4. Others
- 6.3.1.2.2.2. Immunotherapy
- 6.3.1.2.2.3. Targeted Therapy
- 6.3.1.2.2.3.1. Tyrosine Kinase Inhibitors (TKIs)
- 6.3.1.2.2.3.2. Monoclonal Antibodies
- 6.3.1.2.2.3.3. Others
- 6.3.1.2.2.4. Other Hormonal and Supportive Care
- 6.3.1.2.3. By Route of Administration
- 6.3.1.2.3.1. Oral
- 6.3.1.2.3.2. Parenteral
- 6.3.1.2.3.3. Others
- 6.3.1.2.4. By End-user
- 6.3.1.2.4.1. Hospitals
- 6.3.1.2.4.2. Specialty Clinics
- 6.3.1.2.4.3. Others
- 6.3.2. Canada
- 6.3.3. Mexico
- *All segments will be provided for all regions and countries covered
- 7. Europe Metastatic Solid Tumors Market Outlook, 2018-2032F
- 7.1. Germany
- 7.2. France
- 7.3. Italy
- 7.4. United Kingdom
- 7.5. Russia
- 7.6. Netherlands
- 7.7. Spain
- 7.8. Turkey
- 7.9. Poland
- 8. Asia-Pacific Metastatic Solid Tumors Market Outlook, 2018-2032F
- 8.1. India
- 8.2. China
- 8.3. Japan
- 8.4. Australia
- 8.5. Vietnam
- 8.6. South Korea
- 8.7. Indonesia
- 8.8. Philippines
- 9. South America Metastatic Solid Tumors Market Outlook, 2018-2032F
- 9.1. Brazil
- 9.2. Argentina
- 10. Middle East and Africa Metastatic Solid Tumors Market Outlook, 2018-2032F
- 10.1. Saudi Arabia
- 10.2. UAE
- 10.3. South Africa
- 11. Demand Supply Analysis
- 12. Porter’s Five Forces Analysis
- 13. PESTLE Analysis
- 14. Pricing Analysis
- 15. Market Dynamics
- 15.1. Market Drivers
- 15.2. Market Challenges
- 16. Market Trends and Developments
- 17. Regulatory Framework and Innovation
- 17.1. Regulatory Approvals
- 17.2. Clinical Trials
- 18. Patent Landscape
- 19. Case Studies
- 20. Competitive Landscape
- 20.1. Competition Matrix of Top 5 Market Leaders
- 20.2. SWOT Analysis for Top 5 Players
- 20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. Viatris Inc.
- 20.3.1.1. Company Details
- 20.3.1.2. Key Management Personnel
- 20.3.1.3. Products and Services
- 20.3.1.4. Financials (As Reported)
- 20.3.1.5. Key Market Focus and Geographical Presence
- 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 20.3.2. F. Hoffmann-La Roche Ltd
- 20.3.3. AstraZeneca PLC
- 20.3.4. AbbVie Inc.
- 20.3.5. Eli Lilly and Company
- 20.3.6. GlaxoSmithKline plc
- 20.3.7. Novartis AG
- 20.3.8. Amgen Inc.
- 20.3.9. Bayer AG
- 20.3.10. Lupin Limited
- *Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
- 21. Strategic Recommendations
- 22. About Us and Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
